人参皂苷Rh2联合化疗用于肺癌的疗效评价及对肿瘤标志物和免疫功能的影响

Efficacy of ginsenoside Rh2 combined with chemotherapy for lung cancer and its effect on tumor markers and immune function

目的 评价人参皂苷Rh2联合化疗用于肺癌的疗效及对肿瘤标志物和免疫功能的影响。方法 99例肺癌患者按 随机数字表法分为对照组58例和研究组41例,对照组采用顺铂+培美曲赛化疗,研究组在对照组基础上联合人参皂苷Rh2治 疗。比较2组临床疗效,治疗前后肿瘤标志物,免疫功能和不良反应发生情况。结果 治疗后,研究组客观缓解率及临床获益 率高于对照组(P<0.05)。治疗前,2组肿瘤标志物及免疫功能水平比较差异无统计学意义(P>0.05);治疗后,2组肿瘤标 志物水平均下降,研究组低于对照组(P<0.05);对照组CD3^+、CD4^+、CD4^+/CD8^+均下降,CD8^+均上升,和治疗前比较差异 有统计学意义(P<0.05);研究组免疫功能指标与治疗前比较差异无统计学意义(P>0.05)。2组恶心、呕吐,贫血及肝肾功 能异常发生率比较差异无统计学意义(P>0.05);研究组血小板减少及白细胞减少低于对照组(P<0.05)。结论 人参皂苷 Rh2联合化疗用于肺癌的近期疗效良好,可降低肿瘤标志物水平,保护免疫功能,减少化疗药物的毒性反应。

Objective To evaluate the curative effect of ginsenoside Rh 2 combined with chemotherapy for lung cancer and its effect on tumor markers and immune function. Methods Ninety-nine patients with lung cancer were divided into the control group (n=58) and research group (n=41) according to the random number table method. The control group was treated with cisplatin+pemetrexide chemotherapy, while the research group was additionally treated with ginsenoside Rh2. Then, clinical efficacy, tumor markers, immune function, and adverse reactions before and after treatment were compared between the two groups. Results After treatment, the objective remission rate and clinical benefit rate of the research group were higher than those of the control group(P<0.05). Before treatment, there was no significant difference in tumor markers and immune function between the two groups(P>0.05). After treatment, the levels of tumor markers in both groups were decreased, especially in the research group(P<0.05). In the control group, CD3^+, CD4^+, CD4^+/CD8^+ all decreased, but CD8^+ increased, and the difference was statistically significant(P <0.05). There was no significant difference in immunological function between the two groups before treatment (P>0.05). There was no significant difference in the incidence of nausea, vomiting, anemia and liver and kidney dysfunction between the two groups(P>0.05). The rates of thrombocytopenia and leukopenia in the research group were lower than those in the control group(P<0.05). Conclusion Ginsenoside RH 2 combined with chemotherapy has a good short-term efficacy for lung cancer, which can reduce the levels of tumor markers, protect immune function and reduce the toxic reaction of chemotherapy drugs.